| Literature DB >> 31213798 |
A Duarte-de-Araújo1,2,3, P Teixeira1,2, V Hespanhol4,5, J Correia-de-Sousa1,2,6.
Abstract
Background and objectives: Inhalers mishandling remain an important clinical issue worldwide. The aim of this study was to evaluate inhalation technique in stable COPD out-patients. The variables under study were type of inhaler device (ID), patients' preference for an inhaler, number of IDs used by each patient, beliefs about inhaler medication and some demographic, clinical and functional patients' characteristics. We aim to assess how they are related to inhalation technique.Entities:
Keywords: COPD; Inhalation technique; Inhaler devices
Mesh:
Substances:
Year: 2019 PMID: 31213798 PMCID: PMC6549399 DOI: 10.2147/COPD.S178040
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Checklist of steps for a correct inhalation technique
| 1 | Correct priming or loading |
| 2 | Exhalation before inhalation. |
| 3 | Correct inhalation |
| 4 | Hold the breath a few seconds after inhalation (except when using a pMDI + spacer). |
| 5 | Finalization (clean the mouth-piece, remove used capsule after verifying that no powder remains, check color changing in control window, close ID and wash the mouth if necessary). |
Critical errors in different IDs
| 1 | Aeroliser®, Breezhaler®, and Handihaler®: failure to insert the capsule, failure to press and release buttons, powder remaining in the capsule after inhalation. |
| 2 | Diskus®: failure to open the cover, to slide the lever until it clicks, or not keeping inhaler horizontally. |
| 3 | Ellipta®: failure to slide cover down until a click is heard or block air vent with fingers. |
| 4 | Genuair®: failure to remove the cap, to press and release the button until the control window has changed to green, not holding inhaler horizontally, and not changing control window to red after inhalation. |
| 5 | pMDI: failure to remove cap, not shaking the inhaler (suspensions only), not holding the inhaler in the upright position, poorly synchronized hand actuation and inhalation (except using a spacer), inhalation through the nose, actuation against teeth, lips or tongue. |
| 6 | Respimat®: lack of cartridge in the device, failure to open the cap, twisting the base or pressing the dose-release button, poorly synchronized hand actuation and inhalation. |
| 7 | Spiromax®: failure to hold the inhaler in upright position, failure to open mouthpiece cover until a click is heard or blocking air vent with fingers. |
| 8 | Turbuhaler®: failure to remove cover, to hold the inhaler upright when twisting the grip (tolerance ±45º) until a click is heard. |
Abbreviation: ID, inhaler device.
Demographic, clinical and functional characteristics of COPD patients
| Characteristics | |
|---|---|
| Male gender | 231 (77.0) |
| Mean age (years) | |
| Total/ male / female | 67.6 / 67.4 / 68.3 |
| Age ≥65 years | 188 (62.7) |
| Education level ≤3 school years | |
| Total; male; female | 89 (29.7); 58 (25.1); 31 (44.9) |
| Very low monthly income (<530 Euros) | |
| Total; male; female | 199 (66.8); 146 (63.5); 53 (77.9) |
| Graffar social classification | |
| I – 2 (0.7); II – 13 (4.4); III – 102 (34.5); IV – 175 (59.1); V – 4 (1.3) | |
| Mean smoking amount (pack/years) | 49.2±32.9 |
| mMRC grade ≥2 | 189 (64.3) |
| CAT score ≥10 | 156 (75.4) |
| Frequent ECOPD (≥2 / last year) | 119 (39.7) |
| Post-bronchodilator FEV1L (%) | 1.35 (53.0) |
| GOLD 2017 stage and classification | |
| I – 30 (10.0); II – 123 (41.0); III – 108 (36.0); IV – 39 (13.0) | |
| A – 62 (20.7); B – 121 (40.3); C – 7 (2.3); D – 110 (36.7) | |
Note: Data shown as mean or nº (%).
Abbreviations: mMRC, Medical Research Council Dyspnea Questionnaire; CAT, COPD Assessment Test; ECOPD, COPD exacerbations.
Inhalation misuse by inhaler devices
| Critical errors (%)a | % of incorrect use | 1 | 2 | 3 | |
|---|---|---|---|---|---|
| 69 | 53.6 | 5.8 | 30.6 | 17.4 | |
| 81 | 28.4 | 0 | 16 | 12.3 | |
| 132 | 24.2 | 9.1 | 5.3 | 9.8 | |
| Breezhaler® | 72 | 19.4 | 6.9 | 5.6 | 6.9 |
| Handihaler® | 51 | 37.3 | 13.7 | 5.9 | 17.6 |
| Aeroliser® | 9 | 0 | 0 | 0 | 0 |
| 239 | 26.8 | 8.4 | 11.3 | 7.1 | |
| Diskus® | 75 | 29.3 | 2.7 | 16 | 10.7 |
| Genuair® | 53 | 22.6 | 11.3 | 5.7 | 5.7 |
| Spiromax® | 43 | 25.6 | 0 | 20.9 | 4.7 |
| Turbuhaler® | 37 | 35.1 | 29.7 | 2.7 | 2.7 |
| Ellipta® | 31 | 16.1 | 3.2 | 6.5 | 6.5 |
| ( | ( | ||||
Notes: aCritical errors related to: 1=priming/loading; 2=inhalation maneuver; 3=1+2. bIncorrect use=presence of critical errors.
Inhalers misuse by patients’ characteristics
| CUR | CER | ABL | ||||
|---|---|---|---|---|---|---|
| Male gender | 0.8116 | 0.1618 | 0.7454 | |||
| Female gender | 0.6899 | 0.001 | 0.3284 | 0.001 | 0.5616 | 0.001 |
| Education level <4 years | 0.7171 | 0.2591 | 0.5991 | |||
| Education level ≥4 years | 0.8117 | 0.003 | 0.1753 | 0.026 | 0.7470 | 0.004 |
| Graffar 4+5 | 0.7264 | 0.2472 | 0.6269 | |||
| Graffar 1+2+3 | 0.8654 | 0.001 | 0.1308 | 0.001 | 0.8180 | 0.001 |
Note: Data shown as mean score.
Abbreviations: CUR, correct use rate of inhalers; CER, critical errors rate; ABL, patients’ ability to use inhalers; Graffar, Graffar social classification.
Figure 1Necessity beliefs as a predictor of errors.
Figure 2Necessity beliefs as a predictor of patients’ ability.